Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.For the use of absorbency BCM-95 curcumin and specialised BosPure boswellia in multiple EuroPharma formulations
Subscribe to our email newsletter
EuroPharma has signed an exclusive multi-year contract with DolCas Biotech (DolCas) for the use of absorbency BCM-95 curcumin and specialised BosPure boswellia in multiple EuroPharma formulations.
Reportedly, the exclusive distribution territory for these clinically-studied ingredients includes health food store channel and professional channel, involving allopathic doctors, chiropractors, naturopathic doctors, and clinics.
BCM-95 is highly absorbable curcumin. Human clinical data indicates that BCM-95 is up to 10 times more absorbable than curcumin 95% and 6.3 times more absorbable than curcumin with lecithin and piperine.
BosPure boswellia is beta-boswellic acid free, and standardised to contain 10-15% AKBA (Acetyl-11-Keto-Beta-Boswellic Acid), which enhances its targeted impact on the body’s natural anti-inflammatory response.
EuroPharma has agreed to support the marketing, promotion and distribution of BCM-95 and BosPure formulas with a targeted multi-million-dollar marketing investment.
Terry Lemerond, president and founder of EuroPharma, said: “We are proud to enter into this agreement, not only because BCM-95 curcumin and BosPure boswellia are in supplement research, but because we are proud to represent such a fine partner in DolCas Biotech.”
The company said that further research is being conducted on BCM-95 and BosPure and results will be published in near future.